Literature DB >> 24371119

Transcriptional regulators Myb and BCL11A interplay with DNA methyltransferase 1 in developmental silencing of embryonic and fetal β-like globin genes.

Mark Roosjen1, Bradley McColl, Betty Kao, Linden J Gearing, Marnie E Blewitt, Jim Vadolas.   

Abstract

The clinical symptoms of hemoglobin disorders such as β-thalassemia and sickle cell anemia are significantly ameliorated by the persistent expression of γ-globin after birth. This knowledge has driven the discovery of important regulators that silence γ-globin postnatally. Improved understanding of the γ- to β-globin switching mechanism holds the key to devising targeted therapies for β-hemoglobinopathies. To further investigate this mechanism, we used the murine erythroleukemic (MEL) cell line containing an intact 183-kb human β-globin locus, in which the (G)γ- and β-globin genes are replaced by DsRed and eGFP fluorescent reporters, respectively. Following RNA interference (RNAi)-mediated knockdown of two key transcriptional regulators, Myb and BCL11A, we observed a derepression of γ-globin, measured by DsRed fluorescence and qRT-PCR (P<0.001). Interestingly, double knockdown of Myb and DNA methyltransferase 1 (DNMT1) resulted in a robust induction of ε-globin, (up to 20% of total β-like globin species) compared to single knockdowns (P<0.001). Conversely, double knockdowns of BCL11A and DNMT1 enhanced γ-globin expression (up to 90% of total β-like globin species) compared to single knockdowns (P<0.001). Moreover, following RNAi treatment, expression of human β-like globin genes mirrored the expression levels of their endogenous murine counterparts. These results demonstrate that Myb and BCL11A cooperate with DNMT1 to achieve developmental repression of embryonic and fetal β-like globin genes in the adult erythroid environment.

Entities:  

Keywords:  RNA interference; epigenetic repressor; molecular mechanism; β-hemoglobinopathies

Mesh:

Substances:

Year:  2013        PMID: 24371119     DOI: 10.1096/fj.13-242669

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  7 in total

Review 1.  Minireview: Multiomic candidate biomarkers for clinical manifestations of sickle cell severity: Early steps to precision medicine.

Authors:  Steven R Goodman; Betty S Pace; Kirk C Hansen; Angelo D'alessandro; Yang Xia; Ovidiu Daescu; Stephen J Glatt
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-27

2.  Epigenetic inactivation of ERF reactivates γ-globin expression in β-thalassemia.

Authors:  Xiuqin Bao; Xinhua Zhang; Liren Wang; Zhongju Wang; Jin Huang; Qianqian Zhang; Yuhua Ye; Yongqiong Liu; Diyu Chen; Yangjin Zuo; Qifa Liu; Peng Xu; Binbin Huang; Jianpei Fang; Jinquan Lao; Xiaoqin Feng; Yafeng Li; Ryo Kurita; Yukio Nakamura; Weiwei Yu; Cunxiang Ju; Chunbo Huang; Narla Mohandas; Dali Li; Cunyou Zhao; Xiangmin Xu
Journal:  Am J Hum Genet       Date:  2021-03-17       Impact factor: 11.025

Review 3.  5-Aza-4'-thio-2'-deoxycytidine, a New Orally Bioavailable Nontoxic "Best-in-Class": DNA Methyltransferase 1-Depleting Agent in Clinical Development.

Authors:  William B Parker; Jaideep V Thottassery
Journal:  J Pharmacol Exp Ther       Date:  2021-09-09       Impact factor: 4.402

Review 4.  Recent trends in the gene therapy of β-thalassemia.

Authors:  Alessia Finotti; Laura Breda; Carsten W Lederer; Nicoletta Bianchi; Cristina Zuccato; Marina Kleanthous; Stefano Rivella; Roberto Gambari
Journal:  J Blood Med       Date:  2015-02-19

Review 5.  Epigenetic Insights and Potential Modifiers as Therapeutic Targets in β-Thalassemia.

Authors:  Nur Atikah Zakaria; Md Asiful Islam; Wan Zaidah Abdullah; Rosnah Bahar; Abdul Aziz Mohamed Yusoff; Ridhwan Abdul Wahab; Shaharum Shamsuddin; Muhammad Farid Johan
Journal:  Biomolecules       Date:  2021-05-18

6.  Development and characterization of K562 cell clones expressing BCL11A-XL: Decreased hemoglobin production with fetal hemoglobin inducers and its rescue with mithramycin.

Authors:  Alessia Finotti; Jessica Gasparello; Giulia Breveglieri; Lucia Carmela Cosenza; Giulia Montagner; Alberto Bresciani; Sergio Altamura; Nicoletta Bianchi; Elisa Martini; Eleonora Gallerani; Monica Borgatti; Roberto Gambari
Journal:  Exp Hematol       Date:  2015-09-03       Impact factor: 3.084

7.  BCL11A: a potential diagnostic biomarker and therapeutic target in human diseases.

Authors:  Jiawei Yin; Xiaoli Xie; Yufu Ye; Lijuan Wang; Fengyuan Che
Journal:  Biosci Rep       Date:  2019-11-29       Impact factor: 3.840

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.